drugset
drugset / Trial / NCT05613348

CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma

NCT05613348 ↗

Phase 1/2 Withdrawn Zhujiang Hospital Guangdong Zhaotai Cell Bio-tech Co., LTD · collab
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the safety and efficacy of humanized Anti-CD19 Chimeric Antigen Receptor-T cell (CAR19T2 T cell) in children with refractory/relapsed B-cell acute lymphoblastic leukemia/lymphoma.

Timeline

Start
2022-12-01
Primary completion
2025-12-01
Completion
2028-12-01

Outcome

Outcome not reported

Stopped: “The company failed to provide corresponding CART services.”

Drugs

EvaluationDrugModalityDoseRoute
Subject CAR19T2 T cells Cell therapy — —
Background Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Background Cyclophosphamide Other / unclassified 500 mg/m2 Intravenous
Background Fludarabine Small molecule 20 mg/m2 Intravenous
Background Fludarabine Small molecule 30 mg/m2 Intravenous

Indications

B-cell acute lymphoblastic leukemia